GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » Institutional Ownership

SYRE (Spyre Therapeutics) Institutional Ownership : 63.89% (As of Dec. 11, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Spyre Therapeutics's institutional ownership is 63.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Spyre Therapeutics's Insider Ownership is 4.03%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Spyre Therapeutics's Float Percentage Of Total Shares Outstanding is 86.63%.

Spyre Therapeutics Institutional Ownership Historical Data

The historical data trend for Spyre Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spyre Therapeutics Institutional Ownership Chart

Spyre Therapeutics Historical Data

The historical data trend for Spyre Therapeutics can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 22.72 25.33 23.46 19.22 30.44 35.79 35.80 39.74 40.35 35.57

Spyre Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Spyre Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » Institutional Ownership
Comparable Companies
TIL BIOR CASI COYA DYAI IPA CRVO ASMB LGVN MTNB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Website
https://www.spyre.com
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Executives
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones officer: See Remarks C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle officer: Chief Operating Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson director 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg director, officer: President and CEO C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer officer: Interim CEO & General Counsel ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick officer: Chief Commercial Officer C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746